Brion A, Mahe B, Kolb B, Audhuy B, Colombat P, Maisonneuve H, et al. Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial. Bone Marrow Transplant. 2012;47:542–8.
Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013;27(2):362–9.
Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. Entering the era of targeted therapy for chronic lymphocytic leukemia: Impact on the practicing clinician. J Clin Oncol. 2014;32(27):3039–47.
Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2008:450–6.
Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21:12–17.
Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116(14):2438–47.
Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014;124(26):3841–9.
Efremov DG and Laurenti L. Recent advances in the pathogenesis and treatment of chronic lymphocytic leukemia. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2014;35(3):105–20.
Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v78–v84. e-update available from http://www.esmo.org/Guidelines/Haematological-Malignancies/Chronic-Lymphocytic-Leukaemia (accessed December 2017).
European Medicines Authority (EMA). CHMP confirms recommendations for use of Zydelig. Press release available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/07/news_detail_002573.jsp (accessed October 2017).
Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct;4(10):e475-e486.
Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209–16
Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013;24:561–576.
Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol. 2016;3(7):e317–29.
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. New Engl J Med. 2014;370:1101–1110.
Gladstone DE, Fuchs E. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Curr Opin Oncol. 2012;24(2):176–81.
Gribben J G, Riches J C. Immunotherapeutic strategies including transplantation: eradication of disease. Hematology Am Soc Hematol Educ Program. 2013;2013:151–7.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008;111:5446–56.
Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification and treatment. Am J Hematol. 2017;92:946–65.
Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica 2011;96(5):752–761.
Ibrutinib SPC (Summary of Product Characteristics). Janssen-Cilag Ltd, September 2017.
Ibrutinib Prescribing Information. Janssen Biotech Inc, January 2017.
Idelalisib SPC (Summary of Product Characteristics). Gilead Sciences Ltd, September 2016.
Idelalisib Prescribing Information. Gilead Sciences Inc, September 2016.
Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, et al. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 Sep 21;130(12):1477–80.
Mewawalla P, Nathan S. Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review. Ther Adv Hematol. 2014;5(5):139–152.
Michallet M, Sobh M, Milligan D, Morisset S, Niederwieser D, Koza V, et al. The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia. 2010;24:1725–31.
Oscier D, Dearden C, Erem E, Fegan C, Follows G, Hillmen P, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159:541–64.
Pulte D, Redaniel MT, Bird J, Jeffreys M. Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century. Eur J Haematol. 2015;29(6):540–5.
Stilgenbauer S, Furman RR, Zent CS. Management of Chronic Lymphocytic Leukemia. ASCO Educational Book 2015: 164–175. Available from: http://meetinglibrary.asco.org/EdBook.
van Oers MH, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S, et al., Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015;16(13):1370–9.
Sutton L, Chevret S, Tournilhac O, Diviné M, Leblond V, Corront B, et al. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood. 2011;117:6109–19.
National Comprehensive Cancer Network (NCCN) guidelines 2017 [Accessed 19th March 2017]. Prevention and treatment of cancer-related infections. Available from: http://www.nccn.org.
National Comprehensive Cancer Network (NCCN) guidelines 2017. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Available from: http://www.nccn.org. Accessed: November 2017.
Perumbeti, A. Medscape Reference 2016 [Accessed October 2017]. Hematopoietic Stem Cell Transplantation. Available from: http://emedicine.medscape.com/article/208954-overview.
Schetelig J, van Biezen A, Brand R, Caballero D, Martino R, Itala M, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: A retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol. 2008;26:5094–100.
Seymour JF, Kipps TJ, Eichhorst BF, Hillmen P, D’Rozario JM, Assouline S, et al. LBA-2 Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. Abstract presentation at ASH Annual Meeting & Exposition December 12th 2017. Available from https://ash.confex.com/ash/2017/webprogram/Paper109076.html. Accessed December 2017.